J. Soumerai

发表

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2006, Blood.

Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia

K. Anderson, N. Munshi, S. Treon, 2009, Clinical Cancer Research.

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

E. Kimby, P. Morel, S. Treon, 2008, Blood.

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

N. Munshi, S. Treon, Z. Hunter, 2008, Blood.

Macroglobulinemia CD27-CD70 interactions in the pathogenesis of Waldenstrom's

N. Munshi, Z. Hunter, E. Hatjiharissi, 2008 .

Novel agents in the treatment of Waldenström's macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2007, Clinical lymphoma & myeloma.

Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease

D. Neuberg, M. Hellmann, A. Sohani, 2014, Leukemia & lymphoma.

Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.

A. Zelenetz, A. Iasonos, A. Stathis, 2022, The Lancet. Oncology.

Case 16-2022: A 55-Year-Old Man with Fevers, Night Sweats, and a Mediastinal Mass.

D. Fajgenbaum, Reece J. Goiffon, J. Soumerai, 2022, The New England journal of medicine.

TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA

A. Zelenetz, A. Younes, A. Alperovich, 2017, Leukemia & lymphoma.

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

P. Riedell, T. Kipps, K. Dorritie, 2021, Blood.

Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials

Jeffrey A Jones, A. Zelenetz, M. Hallek, 2018, Leukemia & lymphoma.

Case 7-2019: A 73-Year-Old Woman with Swelling of the Right Groin and Fever.

Shahein H. Tajmir, M. Hirsch, J. Soumerai, 2019, The New England journal of medicine.

Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.

Jeffrey A Jones, J. Byrd, A. Zelenetz, 2019, The Lancet. Haematology.

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

S. Treon, I. Ghobrial, J. Castillo, 2020, Blood.

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

D. Esseltine, S. Treon, I. Ghobrial, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

S. Treon, Z. Hunter, L. Ioakimidis, 2009, Clinical lymphoma & myeloma.

Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia

S. Verselis, E. Fox, S. Treon, 2009, British journal of haematology.

Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.

S. Treon, Z. Hunter, L. Ioakimidis, 2011, Blood.

The HMG‐CoA inhibitor, simvastatin, triggers in vitro anti‐tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia

S. Treon, A. Roccaro, A. Sacco, 2008, British journal of haematology.

Alcohol use and health care utilization in rural Liberia: Results of a community-based survey for basic public health indicators

M. Siedner, A. Weil, Patrick T. Lee, 2014 .

Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.

S. Treon, A. Roccaro, A. Sacco, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

Matthew J. Frigault, C. Jacobson, N. Raje, 2022, Blood Cancer Journal.

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia

D. Neuberg, P. Armand, M. Davids, 2019, Leukemia & lymphoma.

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.

Matthew J. Frigault, T. Batchelor, D. Forst, 2019, Blood.

Diagnosis and management of Castleman disease.

A. Sohani, J. Abramson, J. Soumerai, 2014, Cancer control : journal of the Moffitt Cancer Center.

Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.

P. Richardson, D. DeAngelo, E. Jacobsen, 2008 .

The immunophenotypic spectrum of primary mediastinal large B‐cell lymphoma reveals prognostic biomarkers associated with outcome

N. Harris, Jacob R. Bledsoe, A. Sohani, 2016, American journal of hematology.

Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients

P. Riedell, T. Kipps, K. Dorritie, 2020 .

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.

V. Seshan, A. Zelenetz, O. Abdel-Wahab, 2021, The Lancet. Haematology.

The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma

A. Zelenetz, A. Younes, A. Alperovich, 2022, Leukemia & lymphoma.

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

V. Seshan, A. Zelenetz, S. Horwitz, 2020, Blood Cancer Journal.

THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND SMALL LYMPHOCYTIC LYMPHOMA (SLL)

A. Iasonos, A. Stathis, J. Pagel, 2019, Hematological Oncology.

Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax.

A. Zelenetz, O. Abdel-Wahab, A. Dogan, 2020 .

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

S. Tyekucheva, M. Davids, D. Fisher, 2020 .

Tolerability and durable respones of the PI3Kδ inhibitor ME-401 administered on an intermittent schedule in relapsed/refractory (R/R) follicular lymphoma (FL) and other B-cell malignancies.

A. Zelenetz, A. Stathis, J. Pagel, 2020 .

Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

A. Zelenetz, A. Iasonos, A. Stathis, 2018, Blood.

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study

G. Alter, S. Fischinger, J. Abramson, 2022, Blood Advances.

Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection

A. Zelenetz, S. Slager, N. Kay, 2022, Leukemia & lymphoma.

Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)

V. Seshan, A. Zelenetz, O. Abdel-Wahab, 2021, Blood.

Thalidomide and rituximab in Waldenstrom macroglobulinemia.

M. Pasmantier, S. Treon, Z. Hunter, 2004, Blood.

Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy.

J. Tamburini, P. Morel, S. Treon, 2009, Clinical lymphoma & myeloma.

macroglobulinemia Long term outcomes to fludarabine and rituximab in Waldenstrom

P. Morel, S. Treon, A. Branagan, 2008 .

Long-term responses to thalidomide and rituximab in Waldenstrom's macroglobulinemia

S. Treon, Z. Hunter, A. Branagan, 2007 .

Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's macroglobulinemia (WM) patients treated with nucleoside analogues

S. Treon, A. Roccaro, I. Ghobrial, 2007 .

Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom’s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.

S. Treon, I. Ghobrial, Z. Hunter, 2006 .

Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: Results of WMCTG trial 02-079.

S. Treon, Z. Hunter, B. Kahl, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative Outcomes Following CP-R, CVP-R and CHOP-R in Patients with Waldenstrom’s Macroglobulinemia.

S. Treon, L. Ioakimidis, C. Patterson, 2008 .

Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia

S. Treon, I. Ghobrial, Z. Hunter, 2007, American journal of hematology.

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma

A. Zelenetz, M. Voss, A. Chen, 2017, Clinical Cancer Research.

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

I. Lossos, A. Zelenetz, F. Awan, 2022, Blood.

TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

K. Dorritie, W. Wierda, T. Siddiqi, 2019, Journal of Clinical Oncology.

Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib

S. Opat, C. Tam, P. Browett, 2021, Blood.

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Jeffrey A Jones, J. Byrd, A. Zelenetz, 2017 .

An evaluation of the chronic lymphocytic leukemia (CLL) international prognostic index as a prognostic tool in patients with relapsed/refractory CLL in idelalisib phase 3 randomized studies.

Jeffrey A Jones, A. Zelenetz, T. Kipps, 2016 .

DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA

V. Seshan, S. Horwitz, J. Gerecitano, 2017 .

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

A. Alencar, S. Tyekucheva, M. Davids, 2022, Blood.

Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed

A. Zelenetz, S. Horwitz, A. Intlekofer, 2016 .

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

P. Riedell, D. Maloney, D. Brander, 2023, The Lancet.

Abnormalities in Lipoprotein Metabolism Provide Insight into Novel Therapeutic Approaches for Waldenstrom’s Macroglobulinemia (WM).

S. Treon, Z. Hunter, X. Leleu, 2006 .

Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia.

S. Treon, I. Ghobrial, Z. Hunter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IgA and IgG Hypogammaglobulinemia Are Associated with Mutations in the APRIL/BLYS Receptor TACI in Waldenstrom’s Macroglobulinemia (WM).

S. Verselis, E. Fox, S. Treon, 2006 .

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

S. Opat, C. Tam, A. Tedeschi, 2022, Blood.

CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data.

S. Opat, C. Tam, P. Browett, 2022, Clinical Lymphoma, Myeloma & Leukemia.

Diagnosis and management of Castleman disease.

A. Sohani, J. Abramson, J. Soumerai, 2014, Cancer control : journal of the Moffitt Cancer Center.

Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2006, Blood.

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.

E. D. Jacobsen, A. LaCasce, D. Neuberg, 2023, JAMA.

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

E. Kimby, P. Morel, S. Treon, 2008, Blood.

Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL).

A. Zelenetz, A. Iasonos, A. Stathis, 2019, Journal of Clinical Oncology.

Thalidomide and rituximab in Waldenstrom macroglobulinemia.

M. Pasmantier, S. Treon, Z. Hunter, 2004, Blood.

Letter to The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19 – infected patients

S. Treon, I. Ghobrial, Guang Yang, 2020 .

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

S. Tyekucheva, M. Davids, D. Fisher, 2019, Blood.